![]() "The strong financial performance was a result of a rise in manufacturing output against consistently high demand in the quarter." ![]() "Lucira's strong fourth quarter is indicative of the inflection point the company is experiencing in its growth," Lucira President and CEO Erik Engelson said in a statement. Analysts had, on average, expected $40.7 million in Q4 revenues. ![]() Driving the increase were sales of the company's over-the-counter Lucira Check-It COVID-19 test kit, which received US Food and Drug Administration Emergency Use Authorization in April 2021, and its prescription Lucira COVID-19 All-In-One test kit, which received FDA authorization in late 2020. 31, Lucira's revenues jumped to $61.1 million from $269,000 in the same quarter the year before. NEW YORK - Lucira Health on Thursday reported a huge year-over-year surge in revenues for the fourth quarter of 2021 on ramped-up manufacture and sale of the company's molecular at-home COVID-19 tests.įor the three-month period ended Dec. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |